Market Overview

Veracyte Announces Proposed Public Offering of Common Stock

Share:

Veracyte, Inc. (NASDAQ:VCYT) today announced that it has commenced an
underwritten public offering of 5,000,000 shares of its common stock.
All of the shares are being offered by Veracyte. In addition, Veracyte
expects to grant the underwriters a 30-day option to purchase up to
750,000 additional shares of its common stock at the public offering
price, less underwriting discounts and commissions. The offering is
subject to market and other conditions, and there can be no assurance as
to whether or when the offering may be completed, or as to the actual
size or terms of the offering.

Veracyte intends to use the net proceeds from the offering for working
capital and other general corporate purposes. Veracyte may also use a
portion of the net proceeds from the offering to acquire or invest in
complementary businesses, technologies or other assets, although it has
no present commitments or agreements to do so.

Leerink Partners and William Blair are acting as joint book-running
managers for the offering and BTIG is acting as lead manager.

The shares will be issued pursuant to a shelf registration statement
previously filed with and subsequently declared effective by the
Securities and Exchange Commission (SEC). A preliminary prospectus
supplement and accompanying prospectus relating to the offering will be
filed with the SEC and will be available on the SEC's website at www.sec.gov.
A copy of the preliminary prospectus supplement and accompanying
prospectus relating to the offering, when available, may be obtained by
contacting Leerink Partners LLC, Attention: Syndicate Department, One
Federal Street, 37th Floor, Boston, Massachusetts 02110, by email at syndicate@leerink.com,
or by telephone at (800) 808-7525, ext. 6132; or William Blair &
Company, L.L.C., Attention: Prospectus Department, The William Blair
Building, 150 North Riverside Plaza, Chicago, Illinois 60606, by email
at prospectus@williamblair.com,
or by telephone at (800) 621-0687.

This press release does not and shall not constitute an offer to sell or
the solicitation of an offer to buy any securities, nor shall there be
any sale of these securities in any state or other jurisdiction in which
such offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or other
jurisdiction. Any offer, if at all, will be made only by means of a
prospectus, including a prospectus supplement, forming a part of the
effective registration statement.

Veracyte, Afirma, Percepta, Envisia, Know by Design, the Veracyte logo
and the Afirma logo are trademarks of Veracyte, Inc.

View Comments and Join the Discussion!